메뉴 건너뛰기




Volumn 38, Issue 4, 2010, Pages 315-330

The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing: The report and recommendations of a ZEBET Expert Meeting

(24)  Adler, Sarah a   Bicker, Gerd b   Bigalke, Hans c   Bishop, Christopher d   Blümel, Jörg e   Dressler, Dirk f   Fitzgerald, Joan g   Gessler, Frank h   Heuschen, Heide i   Kegel, Birgit j   Luch, Andreas a   Milne, Catherine k   Pickett, Andrew l   Ratsch, Heidemarie m   Ruhdel, Irmela n   Sesardic, Dorothea o   Stephens, Martin p   Stiens, Gerhard q   Thornton, Peter D r   Thürmer, René i   more..


Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; ACETYLCHOLINE;

EID: 78349258949     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119291003800401     Document Type: Conference Paper
Times cited : (52)

References (38)
  • 1
    • 79251518729 scopus 로고    scopus 로고
    • Botulinum Toxin Type A for Injection 01/2005:2113
    • Council of Europe Strasbourg, France: Council of Europe
    • Council of Europe (2006). Botulinum Toxin Type A for Injection 01/2005:2113. In European Pharmacopoeia 6.0, pp. 1117-1119. Strasbourg, France: Council of Europe.
    • (2006) European Pharmacopoeia 6.0 , pp. 1117-1119
  • 2
    • 0019619833 scopus 로고
    • The origin, structure, and pharmacological activity of botulinum toxin
    • Simpson, L.L. (1981). The origin, structure, and pharmacological activity of botulinum toxin. Pharmacological Reviews 33, 155-188.
    • (1981) Pharmacological Reviews , vol.33 , pp. 155-188
    • Simpson, L.L.1
  • 3
    • 0031282024 scopus 로고    scopus 로고
    • Recombinant expression and purification of the botulinum neurotoxin type A translocation domain
    • Lacy, D.B. & Stevens, R.C. (1997). Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. Protein Expression & Purification 11, 195-200.
    • (1997) Protein Expression & Purification , vol.11 , pp. 195-200
    • Lacy, D.B.1    Stevens, R.C.2
  • 4
    • 0033887403 scopus 로고    scopus 로고
    • Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0Å resolution
    • Hanson, M.A. & Stevens, R.C. (2000). Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0Å resolution. Nature Structural Biology 7, 687-692.
    • (2000) Nature Structural Biology , vol.7 , pp. 687-692
    • Hanson, M.A.1    Stevens, R.C.2
  • 5
    • 0018906584 scopus 로고
    • Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction
    • Simpson, L.L. (1980). Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. Journal of Pharmacology & Experimental Therapeutics 212, 16-21.
    • (1980) Journal of Pharmacology & Experimental Therapeutics , vol.212 , pp. 16-21
    • Simpson, L.L.1
  • 6
    • 0021243873 scopus 로고
    • Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization
    • Dolly, J.O., Black, J., Williams, R.S. & Melling, J. (1984). Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature, London 307, 457-460.
    • (1984) Nature, London , vol.307 , pp. 457-460
    • Dolly, J.O.1    Black, J.2    Williams, R.S.3    Melling, J.4
  • 7
    • 0022555430 scopus 로고
    • Molecular pharmacology of botulinum toxin and tetanus toxin
    • Simpson, L.L. (1986). Molecular pharmacology of botulinum toxin and tetanus toxin. Annual Review of Pharmacology & Toxicology 26, 427-453.
    • (1986) Annual Review of Pharmacology & Toxicology , vol.26 , pp. 427-453
    • Simpson, L.L.1
  • 8
    • 0022556315 scopus 로고
    • 125I-labeled botulinum neurotoxins with nerve terminals. II: Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis
    • 125I- labeled botulinum neurotoxins with nerve terminals. II: Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. Journal of Cell Biology 103, 535-544.
    • (1986) Journal of Cell Biology , vol.103 , pp. 535-544
    • Black, J.D.1    Dolly, J.O.2
  • 11
    • 0001748577 scopus 로고
    • Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes
    • Anon. 18/12/1986, Available at: (Accessed 22.06.10)
    • Anon. (1986). Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European Communities L358, 18/12/1986, 1-28. Available at: http://eur-lex.europa.eu/smartapi/cgi/sga-doc? smartapi!celexplus! prod!DocNumber&lg=en&type-doc=Directive &an-doc=86&nu-doc=609 (Accessed 22.06.10).
    • (1986) Official Journal of the European Communities , vol.L358 , pp. 1-28
  • 12
    • 0012111484 scopus 로고    scopus 로고
    • Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
    • Anon. 28/11/2001, Available at: (Accessed 24.06.10)
    • Anon. (2001). Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Official Journal of the European Communities L311, 28/11/2001, 67-128. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri= CELEX:32001L0083:EN:NOT (Accessed 24.06.10).
    • (2001) Official Journal of the European Communities , vol.L311 , pp. 67-128
  • 13
    • 14544300321 scopus 로고    scopus 로고
    • Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use
    • Anon. 30/04/2004, Available at: (Accessed 05.05.10)
    • Anon. (1996). Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Communities L136, 30/04/2004, 34-57. Available at: http://eur-lex.europa.eu/ LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0034:0057:EN:PDF (Accessed 05.05.10).
    • (1996) Official Journal of the European Communities , vol.L136 , pp. 34-57
  • 14
    • 79251495898 scopus 로고    scopus 로고
    • Botulinum toxin type A for injection
    • Anon.
    • Anon. (2009). Botulinum toxin type A for injection. Pharmeuropa 21.3, 361-363.
    • (2009) Pharmeuropa , vol.21 , Issue.3 , pp. 361-363
  • 15
    • 79251507772 scopus 로고    scopus 로고
    • Botulinum toxin type B for injection
    • Anon.
    • Anon. (2009). Botulinum toxin type B for injection. Pharmeuropa 21.3, 363-365.
    • (2009) Pharmeuropa , vol.21 , Issue.3 , pp. 363-365
  • 17
    • 79251480182 scopus 로고    scopus 로고
    • ICH Harmonised Tripartite Guideline. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, Q5C
    • Available at: (Accessed 24.06.10)
    • ICH (1996). ICH Harmonised Tripartite Guideline. Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, Q5C, 10pp. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org/LOB/media/MEDIA427.pdf (Accessed 24.06.10).
    • (1996) Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use , pp. 10
  • 18
    • 79251522612 scopus 로고    scopus 로고
    • ICH Harmonised Tripartite Guideline. Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, Q5E
    • Available at: (Accessed 24.06.10)
    • ICH (2005). ICH Harmonised Tripartite Guideline. Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, Q5E, 16pp. Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Available at: http://www.ich.org/LOB/media/MEDIA1196.pdf (Accessed 24.06.10).
    • (2005) Geneva, Switzerland: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use , pp. 16
  • 21
    • 0242659144 scopus 로고    scopus 로고
    • Role for standards in assays of botulinum toxins: International collaborative study of three preparations of botulinum type A toxin
    • Sesardic, D., Leung, T. & Gaines Das, R.E. (2003). Role for standards in assays of botulinum toxins: International collaborative study of three preparations of botulinum type A toxin. Biologicals 31, 265-276.
    • (2003) Biologicals , vol.31 , pp. 265-276
    • Sesardic, D.1    Leung, T.2    Gaines Das, R.E.3
  • 22
    • 0012997805 scopus 로고    scopus 로고
    • Paris, France: Organisation for Economic Co-operation and Development. Available at: (Accessed 24.06.10)
    • OECD (2001). OECD Guideline for the Testing of Chemicals. No. 420. Acute Oral Toxicity: Fixed Dose Procedure, 14pp. Paris, France: Organisation for Economic Co-operation and Development. Available at: http://lysander.sourceoecd. org/vl=942322/cl=12/nw=1/rpsv/cw/vhosts/oecdjournals/1607310x/v1n4/contp1-1.htm (Accessed 24.06.10).
    • (2001) OECD Guideline for the Testing of Chemicals. No. 420. Acute Oral Toxicity: Fixed Dose Procedure , pp. 14
  • 23
    • 0029952424 scopus 로고    scopus 로고
    • Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin
    • Sesardic, D., McLellan, K., Ekong, T.A.N. & Gaines Das, R. (1996). Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacology & Toxicology 78, 283-288.
    • (1996) Pharmacology & Toxicology , vol.78 , pp. 283-288
    • Sesardic, D.1    McLellan, K.2    Ekong, T.A.N.3    Gaines Das, R.4
  • 24
    • 50549084738 scopus 로고    scopus 로고
    • The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations
    • Pickett, A., O'Keeffe, R., Judge, A. & Dodd, S. (2008). The in vivo rat muscle force model is a reliable and clinically relevant test of consistency among botulinum toxin preparations. Toxicon: Official Journal of the International Society on Toxinology 52, 455-464.
    • (2008) Toxicon: Official Journal of the International Society on Toxinology , vol.52 , pp. 455-464
    • Pickett, A.1    O'Keeffe, R.2    Judge, A.3    Dodd, S.4
  • 25
    • 0034797114 scopus 로고    scopus 로고
    • A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice
    • Aoki, K.R. (2001). A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon: Official Journal of the International Society on Toxinology 39, 1815-1820.
    • (2001) Toxicon: Official Journal of the International Society on Toxinology , vol.39 , pp. 1815-1820
    • Aoki, K.R.1
  • 26
    • 0036080424 scopus 로고    scopus 로고
    • Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety
    • Aoki, K.R. (2002). Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon: Official Journal of the International Society on Toxinology 40, 923-928.
    • (2002) Toxicon: Official Journal of the International Society on Toxinology , vol.40 , pp. 923-928
    • Aoki, K.R.1
  • 30
    • 45549085989 scopus 로고    scopus 로고
    • The Intercostal NMJ Assay - A new alternative to the conventional LD50 assay for the determination of the therapeutic potency of botulinum toxin preparations
    • Huber, A., France, R.M., Riccalton-Banks, L., McLaren, J., Cox, H., Quirk, R.A., Shakesheff, K.M., Thompson, D., Panjwani, N., Shipley, S. & Pickett, A. (2008). The Intercostal NMJ Assay - A new alternative to the conventional LD50 assay for the determination of the therapeutic potency of botulinum toxin preparations. ATLA 36, 141-152.
    • (2008) ATLA , vol.36 , pp. 141-152
    • Huber, A.1    France, R.M.2    Riccalton-Banks, L.3    McLaren, J.4    Cox, H.5    Quirk, R.A.6    Shakesheff, K.M.7    Thompson, D.8    Panjwani, N.9    Shipley, S.10    Pickett, A.11
  • 31
    • 34948874826 scopus 로고    scopus 로고
    • A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies
    • Pellett, S., Tepp, W.H., Clancy, C.M., Borodic, G.E. & Johnson, E.A. (2007). A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Letters 581, 4803-4808.
    • (2007) FEBS Letters , vol.581 , pp. 4803-4808
    • Pellett, S.1    Tepp, W.H.2    Clancy, C.M.3    Borodic, G.E.4    Johnson, E.A.5
  • 33
    • 35448951796 scopus 로고    scopus 로고
    • Human model neurons in studies of brain cell damage and neural repair
    • Paquet-Durand, F. & Bicker, G. (2007). Human model neurons in studies of brain cell damage and neural repair. Current Molecular Medicine 7, 541-554.
    • (2007) Current Molecular Medicine , vol.7 , pp. 541-554
    • Paquet-Durand, F.1    Bicker, G.2
  • 34
    • 72249108973 scopus 로고    scopus 로고
    • Synaptic currents and transmitter responses in human NT2 neurons differentiated in aggregate culture
    • Podrygajlo, G., Song, Y., Schlesinger, F., Krampfl, K. & Bicker, G. (2010). Synaptic currents and transmitter responses in human NT2 neurons differentiated in aggregate culture. Neuroscience Letters 468, 207-210.
    • (2010) Neuroscience Letters , vol.468 , pp. 207-210
    • Podrygajlo, G.1    Song, Y.2    Schlesinger, F.3    Krampfl, K.4    Bicker, G.5
  • 35
    • 0030782182 scopus 로고    scopus 로고
    • Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro
    • Ekong, T.A., Feavers, I.M. & Sesardic, D. (1997). Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 143, 3337-3347.
    • (1997) Microbiology , vol.143 , pp. 3337-3347
    • Ekong, T.A.1    Feavers, I.M.2    Sesardic, D.3
  • 38
    • 36849053345 scopus 로고    scopus 로고
    • Development of improved SNAP25 endopeptidase immune-assays for botulinum type A and E toxins
    • Jones, R.G.A., Ochiai, M., Liu, Y., Ekong, T. & Sesardic, D. (2008). Development of improved SNAP25 endopeptidase immune-assays for botulinum type A and E toxins. Journal of Immunological Methods 329, 92-101.
    • (2008) Journal of Immunological Methods , vol.329 , pp. 92-101
    • Jones, R.G.A.1    Ochiai, M.2    Liu, Y.3    Ekong, T.4    Sesardic, D.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.